Anti-Human TIRAP (Intermediate Domain)

Anti-Human TIRAP (Intermediate Domain)

Product No.: T359

[product_table name="All Top" skus="T359"]

- -
- -
Target
TIRAP
Product Type
Polyclonal Antibody
Alternate Names
MAL, TIR Domain Containing Adaptor Protein
Applications
IHC FFPE
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Rabbit
Immunogen
PN:T364
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Human TIRAP recognizes an epitope in the intermediate domain of Human TIRAP. This polyclonal antibody was purified using affinity chromatography.
Background
Toll-like receptors (TLRs) are signaling molecules that recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses (1-3). These proteins act through adaptor molecules such as TIRAP and MyD88 to activate various kinases and transcription factors (4,5). In TIRAP-deficient mice, TLR signaling in response to TLR2 ligands (using either TLR1 and TLR6 as co-receptors) is totally abolished, suggesting that MyD88 and TIRAP work together and are both required for TLR2 signaling (6). Furthermore, these mice are also resistant to the toxic effects of LPS and show defects in NF-κB and MAP kinase activation, suggesting that TIRAP is also involed in TLR4 signaling (6,7).

Antigen Details

PubMed

References & Citations

1. Fenton, MJ. et al. (2003) Mol. Interv. 3:466-77.
2. Akira, S. et al. (2003) Annu.Rev. Immunol. 21:335-76.
3. Janeway Jr., CA. and Medzhitov, R. (2002) Annu. Rev. Immunol. 20:197-216.
4. Bowie, AG. et al. (2003) Trends in Imm. 24:286-9.
5. McGettrick, AF. and O’Neill, LAJ. (2004) MolImm. 41:577-82.
6. Hemmi, H. et al. (2002) Nature 420:324-9.
7. Flavell, RA. et al. (2002) Nature 420:329-333.
IHC FFPE
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.